[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oncotelic Therapeutcs Inc (OTLC)

Oncotelic Therapeutcs Inc (OTLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 17,673
  • Shares Outstanding, K 455,493
  • Annual Sales, $ 0 K
  • Annual Income, $ 249,280 K
  • EBIT $ -5 M
  • EBITDA $ -5 M
  • 60-Month Beta -0.27
  • Price/Sales N/A
  • Price/Cash Flow 0.07
  • Price/Book 0.07
  • Price/Earnings ttm 0.07
  • Earnings Per Share ttm 0.59
  • Most Recent Earnings $0.00 on 05/14/26
  • Next Earnings Date 08/12/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0362 +7.18%
on 07/09/26
0.0538 -27.88%
on 06/15/26
-0.0147 (-27.48%)
since 06/10/26
3-Month
0.0335 +15.82%
on 04/15/26
0.0620 -37.42%
on 05/28/26
+0.0042 (+12.14%)
since 04/10/26
52-Week
0.0150 +158.67%
on 02/11/26
0.1100 -64.73%
on 10/22/25
-0.0122 (-23.92%)
since 07/10/25

Most Recent Stories

More News
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway

Clinical Program Advances Following Favorable Safety Review; Peer-Reviewed Publication Further Validates Deciparticle ™ Platform SAN DIEGO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Oncotelic...

OTLC : 0.0388 (-5.37%)
Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003

Publication Highlights Novel Intravenous Everolimus Formulation and Demonstrates Broad Potential of Deciparticle ™ Technology for Hydrophobic Therapeutics SAN DIEGO, Calif., June 29, 2026...

OTLC : 0.0388 (-5.37%)
Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026

Company to Showcase Integration of AI, Digital Batch Records, and Intelligent Robotics to Accelerate Pharmaceutical Manufacturing AGOURA HILLS, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Oncotelic...

OTLC : 0.0388 (-5.37%)
Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services

SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB: OTLC) today announced the completion of key Phase 2 objectives in its joint manufacturing...

OTLC : 0.0388 (-5.37%)
Oncotelic Showcases PDAOAI™ Capability in Advancing Drug Development. Featured in Qdrant Vector Space Day 2026 Keynote

PDAOAI Platform Indexes 28 Million PubMed Abstracts on Qdrant; Introduces Manifold Folding to Solve the Infinity Problem in Biomedical Knowledge Retrieval AGOURA HILLS, CA, June 08, 2026 (GLOBE...

OTLC : 0.0388 (-5.37%)
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...

OTLC : 0.0388 (-5.37%)
Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

SAN DIEGO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Sapu Nano and Oncotelic Therapeutics (OTCQB:OTLC) today announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus...

OTLC : 0.0388 (-5.37%)
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+...

OTLC : 0.0388 (-5.37%)
TechForce Robotics Enters Pharmaceutical Automation Market Through Initial Deployment at Oncotelic Therapeutics

Deployment of the Company's LIM-E autonomous laboratory support robot completes Phase 1 objectives under the joint development agreement and establishes a foundation for future pharmaceutical automation...

OTLC : 0.0388 (-5.37%)
NGTF : 0.0389 (-1.27%)
Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026

SAN DIEGO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- via IBN -- Sapu Nano and Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) today announced that Vuong Trieu, Chief Executive Officer,...

OTLC : 0.0388 (-5.37%)

Business Summary

Mateon is a biopharmaceutical company focused on the modulation of transforming growth factor-beta (TGF-beta) for the treatment of cancer and infectious diseases, including COVID-19. The company's lead development compound, OT-101 (trabedersen), is a single stranded antisense oligonucleotide targeting...

See More

Key Turning Points

3rd Resistance Point 0.0459
2nd Resistance Point 0.0444
1st Resistance Point 0.0416
Last Price 0.0388
1st Support Level 0.0373
2nd Support Level 0.0358
3rd Support Level 0.0330

See More

52-Week High 0.1100
Fibonacci 61.8% 0.0737
Fibonacci 50% 0.0625
Fibonacci 38.2% 0.0513
Last Price 0.0388
52-Week Low 0.0150

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.